Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,580 matching trials from the live ClinicalTrials.gov search.
Conditions
Pain
Interventions
S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
New York, New York
Conditions
PTCL, CTCL
Interventions
Pembrolizumab, Pralatrexate, Decitabine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 90 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Charlottesville, Virginia
Conditions
Mastocytosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Cutaneous Squamous Cell Carcinoma, Actinic Keratoses, Skin Cancer, Organ Transplant Recipients, Immunotherapy
Interventions
Calcipotriol Only Product in Cutaneous Dose Form, Vaseline, Topical 5FU
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • St Louis, Missouri
Conditions
Breast Cancer
Interventions
SimpliDerm HADM, AlloDerm HADM, AlloMax HADM, FlexHD HADM, DermACELL HADM
Other
Lead sponsor
Elutia Inc.
Industry
Eligibility
Female only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Montgomery, Alabama • Muscle Shoals, Alabama • Nashville, Tennessee + 2 more
Conditions
Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage I Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage II Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Laboratory Biomarker Analysis, Lenalidomide
Drug · Other
Lead sponsor
John Reneau
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Systemic Sclerosis, Scleroderma
Interventions
Tofacitinib, Placebo Oral Tablet
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Ann Arbor, Michigan • Pittsburgh, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers

Tailored Intervention for Melanoma Patient's Families

NCT00816374
Conditions
Melanoma
Interventions
Reading materials and discussions, Questionnaires
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
21 Years and older
Enrollment
553 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
3
States / cities
Tampa, Florida • Philadelphia, Pennsylvania
Conditions
B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Plasma Cell Myeloma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Acute Myeloid Leukemia, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Plasma Cell Myeloma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Positron Emission Tomography, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Single Photon Emission Computed Tomography, Cemiplimab, Ruxolitinib, Nivolumab, Multigated Acquisition Scan, Echocardiography Test, Bone Marrow Aspiration
Procedure · Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Conditions
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7
Interventions
Carmustine, Laboratory Biomarker Analysis, O6-Benzylguanine
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Detroit, Michigan • Cleveland, Ohio • Columbus, Ohio
Conditions
Scleroderma
Interventions
BMS-986020, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
19
States / cities
Scottsdale, Arizona • Los Angeles, California • Stanford, California + 13 more
Conditions
Melanoma
Interventions
AZD6244, Dacarbazine, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Conditions
Cutaneous T-cell Lymphoma (CTCL)
Interventions
Romidepsin, Brentuximab vedotin
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Conditions
Lymphoma
Interventions
temozolomide
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
3
States / cities
New Haven, Connecticut • Chicago, Illinois
Conditions
Melanoma
Interventions
Completion Lymphadenectomy, Monitoring with nodal ultrasound
Procedure
Lead sponsor
Saint John's Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
1,939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
39
States / cities
San Diego, California • Santa Monica, California • Colorado Springs, Colorado + 31 more
Conditions
Hematological Malignancies
Interventions
KPT-330
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
Tampa, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more
Conditions
Erythropoietic Protoporphyria, EPP, X-Linked Protoporphyria, XLP, XLPP, X-Linked Dominant Erythropoietic Protoporphyria, XLEPP, XLDP
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • New York, New York + 3 more
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Topical SLPI on Skin Wounds

NCT00005569
Conditions
Healthy, Wound Healing
Interventions
SLPI (Secretory Leukocyte Protease Inhibitor)
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Systemic Sclerosis, Scleroderma, Diffuse Systemic Sclerosis, Diffuse Scleroderma, Diffuse Cutaneous Systemic Sclerosis, Diffuse Cutaneous Scleroderma, Progressive Systemic Sclerosis, Progressive Scleroderma, Scleroderma, Systemic, Scleroderma, Diffuse, Scleroderma;Progressive, Systemic Sclerosis, Diffuse, Systemic; Sclerosis, Progressive, Scleroderma of Lung, Scleroderma With Pulmonary Involvement, Systemic Sclerosis Pulmonary, Systemic Sclerosis With Lung Involvement, Interstitial Lung Disease, Pulmonary Fibrosis Interstitial
Interventions
Ixazomib
Drug
Lead sponsor
Michael M. Pham
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
Hypogonadism
Interventions
Testosterone MD-Lotion
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
11
States / cities
Birmingham, Alabama • Tuscon, Arizona • Burbank, California + 8 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparative Ultrasound Analysis of Two Hyaluronic Acid Dermal Fillers

NCT05622851
Conditions
Volume Deficiency of the Midface
Interventions
Restylane Contour, Juvederm Voluma
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
22 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Santa Rosa Beach, Florida
Conditions
Adult Immunoblastic Lymphoma, Central Nervous System Non-Hodgkin Lymphoma, Childhood Immunoblastic Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3 Follicular Lymphoma, Lymphoproliferative Disorder, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Non-Hodgkin Lymphoma, Primary Cutaneous B-Cell Non-Hodgkin Lymphoma, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma
Interventions
Cytology Specimen Collection Procedure
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2023
U.S. locations
119
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 93 more
Completed Phase 3 Interventional Accepts healthy volunteers

PREVELLE Shape (CX002) Dermal Filler Protocol

NCT00764257
Conditions
Correction of Nasolabial Folds and Lip Augmentation
Interventions
PREVELLE Shape, Restylane
Device
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Santa Barbara, California
Conditions
Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Basal Cell Carcinoma
Interventions
Copaxone
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Fairway, Kansas • Kansas City, Kansas